Jason joined Oxford BioMedica in 2015 and has been Chief Business Officer since 2018. He has 20 years’ experience in the biotechnology industry in biologics, vaccines and gene therapy. He has worked in international business development roles at Sosei Co., Ltd, and Intercell AG and was co-founder and CEO of ProtAffin AG, a venture capital backed company in Austria and UK. Jason was awarded a 1st class BA (Hons) in Biochemistry from Magdalen College, Oxford University and also completed an PhD in complex disease genetics from Imperial College London. Jason was awarded an MBA with distinction from London Business School.